Literature DB >> 25575134

Notch signaling activation in pediatric low-grade astrocytoma.

William D Brandt1, Karisa C Schreck, Eli E Bar, Isabella Taylor, Luigi Marchionni, Eric Raabe, Charles G Eberhart, Fausto J Rodriguez.   

Abstract

Pilocytic astrocytoma (PA) is the most common primary brain tumor in children; various signaling pathways have been implicated in its biology. The Notch signaling pathway has been found to play a role in the development, stem cell biology, and pathogenesis of several cancers, but its role in PA has not been investigated. We studied alterations in Notch signaling components in tumor tissue from 18 patients with PA and 4 with other low-grade astrocytomas to identify much needed therapeutic targets. We found that Notch pathway members were overexpressed at the mRNA (NOTCH1, NOTCH2, HEY1, HEY2) and protein (HES1) levels in PAs at various anatomic sites compared with non-neoplastic brain samples. These changes were not associated with specific BRAF alterations. Inhibiting the Notch pathway in the pediatric low-grade astrocytoma cell lines Res186 and Res259 using either RNA interference or a γ-secretase inhibitor resulted in variable, but significant, reduction in cell growth and migration. This study suggests a potential role for Notch signaling in pediatric low-grade astrocytoma tumorigenesis and that Notch signaling may be a viable pathway therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25575134      PMCID: PMC4357229          DOI: 10.1097/NEN.0000000000000155

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  46 in total

1.  Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.

Authors:  Karine Jacob; Dongh-Anh Quang-Khuong; David T W Jones; Hendrik Witt; Sally Lambert; Steffen Albrecht; Olaf Witt; Catherine Vezina; Margret Shirinian; Damien Faury; Miklos Garami; Peter Hauser; Almos Klekner; Laszlo Bognar; Jean-Pierre Farmer; Jose-Luis Montes; Jeffrey Atkinson; Cynthia Hawkins; Andrey Korshunov; V Peter Collins; Stefan M Pfister; Uri Tabori; Nada Jabado
Journal:  Clin Cancer Res       Date:  2011-05-24       Impact factor: 12.531

Review 2.  Notch signaling and brain tumors.

Authors:  Marie-Thérése Stockhausen; Karina Kristoffersen; Hans Skovgaard Poulsen
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

3.  EphB signaling controls lineage plasticity of adult neural stem cell niche cells.

Authors:  Tadashi Nomura; Christian Göritz; Timothy Catchpole; Mark Henkemeyer; Jonas Frisén
Journal:  Cell Stem Cell       Date:  2010-12-03       Impact factor: 24.633

4.  Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.

Authors:  Ian Krop; Tim Demuth; Tina Guthrie; Patrick Y Wen; Warren P Mason; Prakash Chinnaiyan; Nicholas Butowski; Morris D Groves; Santosh Kesari; Steven J Freedman; Samuel Blackman; James Watters; Andrey Loboda; Alexei Podtelezhnikov; Jared Lunceford; Cong Chen; Maxine Giannotti; Jeremy Hing; Robert Beckman; Patricia Lorusso
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  Notch signaling promotes growth and invasion in uveal melanoma.

Authors:  Laura Asnaghi; Katayoon B Ebrahimi; Karisa C Schreck; Eli E Bar; Michael L Coonfield; W Robert Bell; James Handa; Shannath L Merbs; J William Harbour; Charles G Eberhart
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

6.  Notch3 activation promotes invasive glioma formation in a tissue site-specific manner.

Authors:  Tarran J Pierfelice; Karisa C Schreck; Louis Dang; Laura Asnaghi; Nicholas Gaiano; Charles G Eberhart
Journal:  Cancer Res       Date:  2011-01-18       Impact factor: 12.701

7.  The oncogenic roles of Notch1 in astrocytic gliomas in vitro and in vivo.

Authors:  Peng Xu; Mingzhe Qiu; Zhiyong Zhang; Chunsheng Kang; Rongcai Jiang; Zhifan Jia; Guangxiu Wang; Hao Jiang; Peiyu Pu
Journal:  J Neurooncol       Date:  2009-09-22       Impact factor: 4.130

8.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.

Authors:  David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister
Journal:  Nat Genet       Date:  2013-06-30       Impact factor: 38.330

9.  Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade.

Authors:  Qian Chu; Brent A Orr; Samantha Semenkow; Eli E Bar; Charles G Eberhart
Journal:  Clin Cancer Res       Date:  2013-04-29       Impact factor: 12.531

10.  Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.

Authors:  Lori A Ramkissoon; Peleg M Horowitz; Justin M Craig; Shakti H Ramkissoon; Benjamin E Rich; Steven E Schumacher; Aaron McKenna; Michael S Lawrence; Guillaume Bergthold; Priscilla K Brastianos; Barbara Tabak; Matthew D Ducar; Paul Van Hummelen; Laura E MacConaill; Tina Pouissant-Young; Yoon-Jae Cho; Hala Taha; Madeha Mahmoud; Daniel C Bowers; Linda Margraf; Uri Tabori; Cynthia Hawkins; Roger J Packer; D Ashley Hill; Scott L Pomeroy; Charles G Eberhart; Ian F Dunn; Liliana Goumnerova; Gad Getz; Jennifer A Chan; Sandro Santagata; William C Hahn; Charles D Stiles; Azra H Ligon; Mark W Kieran; Rameen Beroukhim; Keith L Ligon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-30       Impact factor: 11.205

View more
  1 in total

1.  Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells.

Authors:  Ulf D Kahlert; Abigail K Suwala; Katharina Koch; Manabu Natsumeda; Brent A Orr; Masanori Hayashi; Jarek Maciaczyk; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2015-09       Impact factor: 3.685

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.